secwatch.observer — SEC 8-K summary
======================================

Issuer:     Black Diamond Therapeutics, Inc. (BDTX)
CIK:        0001701541
Form:       8-K
Filed at:   2022-12-12T23:59:59+00:00
Accession:  0001104659-22-126074
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Black Diamond Therapeutics spins out Launchpad Therapeutics with $30M Series A from Versant and NEA
--------------------------------------------------------------------------------

- Spinout of Launchpad, an antibody-focused precision oncology company; $30M Series A led by Versant Ventures and NEA.
- Black Diamond contributed undisclosed early-stage antibody programs and licensed its MAP Drug Discovery Engine to Launchpad.
- Black Diamond received 9.0 million shares of Launchpad common stock (minority stake) for the contributed assets and license.
- Black Diamond will continue focus on BDTX-1535, BDTX-4933, and small molecule pipeline while retaining upside via equity stake.
- Launchpad will use the MAP Engine for large molecule discovery and development of novel antibody therapeutics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701541/000110465922126074/0001104659-22-126074-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701541/000110465922126074/tm2232368d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-126074

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer